For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Neurocrine Biosciences, Inc’s stock clocked out at $95.28, up 8.84% from its previous closing price of $87.54. In other words, the price has increased by $8.84 from its previous closing price. On the day, 2.71 million shares were traded. NBIX stock price reached its highest trading level at $95.54 during the session, while it also had its lowest trading level at $84.23.
Ratios:
To gain a deeper understanding of NBIX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.05. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Hold rating and assigned the stock a target price of $138.
Piper Sandler Upgraded its Neutral to Overweight on August 29, 2024, whereas the target price for the stock was revised from $131 to $159.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 13 ’25 when Cooke Julie sold 1,551 shares for $116.78 per share. The transaction valued at 181,129 led to the insider holds 19,544 shares of the business.
GORMAN KEVIN CHARLES sold 5,844 shares of NBIX for $681,914 on Feb 13 ’25. The Director now owns 521,618 shares after completing the transaction at $116.69 per share. On Feb 13 ’25, another insider, SHERWIN STEPHEN A, who serves as the Director of the company, sold 13,831 shares for $116.69 each. As a result, the insider received 1,613,923 and left with 10,673 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 9499749376 and an Enterprise Value of 8956241920. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.95, and their Forward P/E ratio for the next fiscal year is 15.52. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.77. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.03 while its Price-to-Book (P/B) ratio in mrq is 3.66. Its current Enterprise Value per Revenue stands at 3.803 whereas that against EBITDA is 14.68.
Stock Price History:
The Beta on a monthly basis for NBIX is 0.41, which has changed by -0.299051 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, NBIX has reached a high of $157.98, while it has fallen to a 52-week low of $86.57. The 50-Day Moving Average of the stock is -18.74%, while the 200-Day Moving Average is calculated to be -25.73%.
Shares Statistics:
It appears that NBIX traded 1.40M shares on average per day over the past three months and 1748040 shares per day over the past ten days. A total of 99.40M shares are outstanding, with a floating share count of 96.79M. Insiders hold about 2.92% of the company’s shares, while institutions hold 94.11% stake in the company. Shares short for NBIX as of 1741910400 were 3293529 with a Short Ratio of 2.35, compared to 1739491200 on 3044928. Therefore, it implies a Short% of Shares Outstanding of 3293529 and a Short% of Float of 3.8699999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
